Why it Matters

The American Gastroenterological Association (AGA) continues its strategic shift toward in-house lobbying after decades of relying on external firms. The $80,000 Q2 2025 expenditure reflects the organization’s commitment to direct congressional advocacy. This approach gives AGA immediate control over messaging on critical gastroenterology policy issues.

By the Numbers

  • Q2 2025 spending: $80,000 in in-house lobbying
  • Total historical expenditures: Over $10 million since 2003
  • In-house team: Led by Sarah Hodgkins Ankney and Kathleen Teixeira
  • External partnerships: Ongoing relationship with Hart Health Strategies Inc. ($3.88M since 2003)
  • Ankney’s experience: 13 filings totaling $1.04M since 2022
  • Teixeira’s experience: 75 filings totaling $5.98M since 2003

Broader Context

Physicians faced a 2.8% Medicare payment cut in 2025, creating urgency around payment reform advocacy. Medicare Advantage prior authorization requirements continue to delay patient care access. Obesity treatment coverage remains limited under current Medicare policies, despite growing recognition of obesity as a medical condition.

The Agenda

AGA focused on three specific priorities during Q2 2025. The organization lobbied against Medicare physician payment cuts implemented in 2025. They supported the Improving Seniors Timely Access to Care Act for prior authorization reform. The group also backed the Treat and Reduce Obesity Act to expand Medicare coverage.

Competitive Landscape

The report doesn’t detail other organizations’ lobbying on the same issues. However, physician payment reform typically attracts broad medical association support. Prior authorization reform and obesity treatment coverage likely involve multiple healthcare stakeholders. AGA’s specialized gastroenterology focus differentiates it from broader medical groups.

Between The Lines

The S.1928 – Gerald E. Connolly Esophageal Cancer Awareness Act of 2025 specifically references AGA’s December 2022 screening recommendations. This demonstrates the organization’s policy influence beyond direct lobbying activities. The H.R.2433 – Reducing Medically Unnecessary Delays in Care Act of 2025 aligns with AGA’s prior authorization reform priorities.

The Bottom Line

AGA’s in-house lobbying strategy provides direct control over gastroenterology policy advocacy. The organization maintains focused priorities while leveraging experienced lobbyists’ congressional relationships. This approach appears sustainable given AGA’s consistent policy engagement over two decades.

Spot something wrong? Report an issue with this article